ArticleCellular and molecular life sciences : CMLS2009
Differential use of an in-frame translation initiation codon regulates human mu opioid receptor (OPRM1).
Article in Cellular and molecular life sciences : CMLS, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Elevating plant immunity by translational regulation of a rice WRKY transcription factor.Plant biotechnology journal · 2024Article
- N-terminal proteoforms may engage in different protein complexes.Life science alliance · 2023Article
- Epigenetic Modulation of Opioid Receptors by Drugs of Abuse.International journal of molecular sciences · 2022Review
- Construction of anti-codon table of the plant kingdom and evolution of tRNA selenocysteine (tRNABMC genomics · 2020Article
- Post-Transcriptional Regulation of the Human Mu-Opioid Receptor (MOR) by Morphine-Induced RNA Binding Proteins hnRNP K and PCBP1.Journal of cellular physiology · 2017Article
- Positional proteomics reveals differences in N-terminal proteoform stability.Molecular systems biology · 2016Article
- N-terminal proteomics and ribosome profiling provide a comprehensive view of the alternative translation initiation landscape in mice and men.Molecular & cellular proteomics : MCP · 2014Article
- Roles of the ubiquitin proteasome system in the effects of drugs of abuse.Frontiers in molecular neuroscience · 2014Review
- Vimentin interacts with the 5'-untranslated region of mouse mu opioid receptor (MOR) and is required for post-transcriptional regulation.RNA biology · 2013Article
- Post-transcriptional regulation of mu-opioid receptor: role of the RNA-binding proteins heterogeneous nuclear ribonucleoprotein H1 and F.Cellular and molecular life sciences : CMLS · 2012Article
- Exploring the selective constraint on the sizes of insertions and deletions in 5' untranslated regions in mammals.BMC evolutionary biology · 2011Article
- Translation initiation: variations in the mechanism can be anticipated.Cellular and molecular life sciences : CMLS · 2011Review
- Transcriptional and epigenetic regulation of opioid receptor genes: present and future.Annual review of pharmacology and toxicology · 2011Review
- Up-regulation of the mu-opioid receptor gene is mediated through chromatin remodeling and transcriptional factors in differentiated neuronal cells.Molecular pharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The pharmacological effects of morphine and morphine-like drugs are mediated primarily through the micro opioid receptor. Here we show that differential use of an in-frame translational start codon in the 5'-untranslated region of the OPRM1 generates different translational products in vivo and in vitro. The 5'-end of the OPRM1 gene is necessary for initiating the alternate form and for subsequent degradation of the protein. Initiation of OPRM1 at the upstream site decreases the initiation at the main AUG site. However, alternative initiation of the long form of OPRM1 produces a protein with a short half-life, resulting from degradation mediated by the ubiquitin-proteasome pathway. Reporter and degradation assays showed that mutations of this long form at the second and third lysines reduce ubiquitin-dependent proteasome degradation, stabilizing the protein. The data suggest that MOP expression is controlled in part by initiation of the long form of MOP at the alternate site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.